<DOC>
	<DOCNO>NCT00712582</DOCNO>
	<brief_summary>About 60 % patient DLBCL cure chemotherapy program . It call RCHOP-21 ( Rituximab , Cyclophosphamide , Doxorubicin , Vincristine , Prednisone ) . It give every 3 week , 18 week . Each three week cycle . Some factor predict may cure R-CHOP-21 . The common one : - Stage - much DLBCL , PMBL , FL3B - LDH - blood chemistry marker ; - Whether normal daily activity . ( performance status ) We think best way cure patient poor risk factor add new treatment R-CHOP . You get different chemotherapy 4 cycle . This type treatment call risk-adapted therapy .</brief_summary>
	<brief_title>Therapy Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk , High-Intermediate Risk , High Risk Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Histologic diagnosis diffuse large B cell lymphoma , PMLBL , follicular lymphoma grade 3B confirm department hematopathology MSKCC : Patients discordant bone marrow involvement ( i.e . involvement small cleave cell small lymphocytic lymphoma ) eligible . Tumors express CD20 determine immunohistochemistry . Ki67 evaluation tumor tissue Patients must stage III , IV disease . Patients IIX , disease must least one ageadjusted IPI risk factor . KPS ≤ 70 LDH &gt; upper limit normal All patient must FDGPET avid ( minimum SUV 2.5 ) measurable disease Patients must normal baseline cardiac function base upon echocardiogram gate blood pool scan ( MUGA ) ejection fraction ≥ 50 % Patients must serum creatinine ≤ 1.5 mg/dl ; creatinine &gt; 1.5 mg/dl creatinine clearance must &gt; 60 ml/minute . Patients must ANC &gt; 1000/mcl Platelets &gt; 50,000/mcl . If patient cytopenia due bone marrow involvement , requirement applicable . Patients must bilirubin level &lt; 2.0 mg/dl absence history Gilbert 's disease ( pattern consistent Gilbert 's ) Patients must Hepatitis B surface antigen negative , Hepatitis B core antibody negative , Hepatitis C negative . All patient childbearing child create age must use acceptable form birth control initiation treatment study 1 year completion chemotherapy and/or transplant . Women premenopausal must negative pregnancy test Age 18 65 Patients must HIV negative . This test may pending patient without risk factor , determine patient 's physician . If patient history malignancy cutaneous basal cell squamous cell carcinoma , must diseasefree ≥ 5 year time enrollment . Patients guardian must capable provide informed consent . Patients must suitable undergo stem cell transplant . Any lymphoma subtype DLBCL , PMLBL , follicular lymphoma grade 3B Patients either parenchymal brain leptomeningeal involvement . No 14 day prednisone therapy diagnostic biopsy either DLBCL , PMLBL , follicular lymphoma grade 3B initiation treatment study . Known pregnancy breastfeed Medical illness unrelated NHL opinion attend physician principal investigator preclude administration chemotherapy safely . This include patient uncontrolled infection , chronic renal insufficiency , myocardial infarction within past 6 month , unstable angina , cardiac arrhythmia chronic atrial fibrillation chronic active persistent hepatitis , New York Heart Association Classification III IV heart disease . History malignancy diseasefree interval &lt; 5 year , exclude curatively treat cutaneous basal cell squamous cell carcinoma carcinoma insitu cervix .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-Hodgkin</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Vincristine</keyword>
	<keyword>ifosfamide</keyword>
	<keyword>etoposide</keyword>
	<keyword>carboplatin</keyword>
	<keyword>stem cell transplant</keyword>
	<keyword>08-026</keyword>
</DOC>